Drug Interaction Report
2 potential interactions and/or warnings found for the following 2 drugs:
- atrasentan
- telaprevir
Interactions between your drugs
telaprevir atrasentan
Applies to: telaprevir, atrasentan
Consumer information for this interaction is not currently available.
GENERALLY AVOID: Coadministration with inhibitors of the hepatic influx transporters organic anion transporting polypeptides (OATP) 1B1 and/or 1B3 may increase the plasma concentrations and adverse effects of atrasentan. In clinical studies, coadministration with the OATP1B1 and 1B3 inhibitor cyclosporine increased the mean systemic exposure (AUC) and peak plasma concentration (Cmax) of atrasentan (single dose, 10 mg) by 380% and 430%, respectively. The risk of adverse effects such as edema, hepatotoxicity and anemia may be increased with this combination.
MANAGEMENT: Concomitant use of atrasentan with OATP1B1 and/or 1B3 inhibitors should generally be avoided.
Drug and food interactions
telaprevir food
Applies to: telaprevir
Food significantly increases the absorption of telaprevir. Within 30 minutes before you take each dose of telaprevir, you should eat a meal or snack containing approximately 20 grams of fat. Taking it on an empty stomach may lead to inadequate blood levels and reduced effectiveness of the medication. Examples of some foods that could be taken with telaprevir include: bagel with cream cheese; half cup of nuts; 3 tablespoons of peanut butter; 1 cup of ice cream; 2 ounces of American or cheddar cheese; 2 ounces of potato chips; or half cup of trail mix. Talk to your healthcare provider if you have additional questions about how to take telaprevir.
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
Filspari
Filspari is used for primary immunoglobulin A nephropathy (IgAN), to slow kidney function decline ...
Botox
Botox is used for cosmetic purposes and to treat overactive bladder symptoms, urinary incontinence ...
Pulmicort Turbuhaler
Pulmicort (budesonide) is used to prevent asthma attacks. Includes Pulmicort side effects ...
Cytoxan
Cytoxan is used for acute lymphocytic leukemia, acute nonlymphocytic leukemia, breast cancer ...
Eohilia
Eohilia (budesonide) suspension is used to treat eosinophilic esophagitis (EoE), to reduce symptoms ...
Fabhalta
Fabhalta is used to treat paroxysmal nocturnal hemoglobinuria (PNH), primary immunoglobulin A ...
Vanrafia
Vanrafia (atrasentan) is a once-a-day non-steroidal tablet used for immunoglobulin A nephropathy ...
Entocort EC
Entocort EC is used to treat active, mild to moderate Crohn's disease (CD) that involves the ileum ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.